Skip to main content

Volume 3 Supplement 1

Abstracts of the Breast Cancer Immunotherapy Symposium (BRECIS): Sidra Symposia Series

Toward the identification of genetic determinants of breast cancer immune responsiveness

Overlapping immune signatures are observed among cancers with a better prognostic connotation and those with an increased likelihood to respond to immunotherapeutic approaches [1, 2]. Such signatures qualitatively overlap with those detected during other conditions of immune-mediated tissue destruction such as flares of autoimmunity or allograft rejection [3]. These pathways reflect a process characterized by the coordinated activation of interferon stimulated genes (ISGs), the recruitment of cytotoxic cells through the production of specific chemokine ligands (CXCR3 and CCR5 ligands), and the activation of immune effector function (IEF) genes [4]. We refer to these genes as the Immunologic Constant of Rejection (ICR) [24]. Here, we tested up-front the prognostic role of the ICR genes in the TCGA (The Cancer Genome Atlas) breast cancer database. We show that ICR genes can segregate breast cancers in different immune phenotypes characterized by distinctive prognostic connotations. Whether the favorable cancer immune phenotype is driven by the intrinsic genetics of the tumor cells is presently unknown. By mining copy number variation, gene-expression, and exome sequencing data we are currently characterizing breast cancer somatic alterations implicated in the development of this favorable cancer immune phenotype. The results of this analysis will be presented and discussed.


  1. 1.

    Bedognetti D., Spivey T. L., Zhao Y., Uccellini L., Tomei S., Dudley M. E., Ascierto M. L., De Giorgi V., Liu Q., Delogu L. G., Sommariva M., Sertoli M. R., Simon R., Wang E., Rosenberg S. A., Marincola F. M.: CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. British journal of cancer. 2013, 109 (9): 2412-23. 10.1038/bjc.2013.557.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  2. 2.

    Galon J., Angell H. K., Bedognetti D., Marincola F. M.: The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. Immunity. 2013, 39 (1): 11-26. 10.1016/j.immuni.2013.07.008.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Spivey T. L., Uccellini L., Ascierto M. L., Zoppoli G., De Giorgi V., Delogu L. G., Engle A. M., Thomas J. M., Wang E., Marincola F. M., Bedognetti D.: Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med. 2011, 9: 174-10.1186/1479-5876-9-174.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  4. 4.

    Wang E., Bedognetti D., Marincola F. M.: Prediction of Response to Anticancer Immunotherapy Using Gene Signatures. J Clin Oncol. 2013, 31 (19): 2369-2371. 10.1200/JCO.2013.49.2157.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Davide Bedognetti.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Simeone, I., Hendrickx, W., Miller, L. et al. Toward the identification of genetic determinants of breast cancer immune responsiveness. j. immunotherapy cancer 3, P1 (2015).

Download citation


  • Breast Cancer
  • Copy Number Variation
  • Exome Sequencing
  • Immunotherapeutic Approach
  • Interferon Stimulate Gene